Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are age-related diseases associated with complications of metabolic syndrome (MetS).^[@bib1]^ However, the molecular underpinnings of prostatic susceptibility to systemic metabolic dysfunction are poorly understood, in part because dietary and transgenic animal models display a limited recapitulation of human benign growth and stromal expansion or adenocarcinoma. Furthermore, unlike adipose, muscle and liver, understanding of the effects of systemic metabolic stressors on prostate growth and/or transformation are hampered by a limited understanding of the prostate\'s normal nutritional metabolism.

Epidemiological links between BPH and diabetes have been recognized for many years^[@bib2]^ and recent studies have demonstrated that the incidence and severity of BPH are correlated with obesity, atherosclerosis, diabetes mellitus, hyperinsulinemia, hyperglycemia and hypercholesterolemia.^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ Although diabetes mellitus has a negative correlation with the incidence of multiple cancers including prostate, diabetic patients exhibit increased mortality.^[@bib8]^ Moreover, MetS as a set of comorbidities (obesity, insulin resistance, dyslipidemia and hypertension) is correlated with PCa incidence.^[@bib9]^ Such associations have prompted the investigation of metabolic genes and potential metabolic therapies in benign and malignant prostatic diseases.^[@bib3],\ [@bib10]^

The peroxisome proliferator-activated receptors (PPARs) are a family of nuclear fatty acid receptors that regulate tissue-specific cellular metabolism and differentiation and have been widely sought after therapeutic targets for a number of obesity-related metabolic diseases owing to their ability to regulate glucose and fatty acid metabolism.^[@bib11],\ [@bib12]^ A class of PPARgamma (PPAR*γ*) agonists called thiazolidinediones (TZDs) are used in the treatment of insulin resistance and regulate a wide range of genes with tissue-specific effects.^[@bib13]^

Historically, PPAR*γ* has been associated with pre-adipocyte expansion and differentiation,^[@bib14]^ but other tissues also show a functional role for PPAR*γ,* including liver^[@bib15]^ and muscle.^[@bib16]^ We showed previously that PPAR*γ* ablation in mouse prostate causes tumorigenesis and active autophagy,^[@bib17],\ [@bib18]^ suggesting PPAR*γ* may provide a molecular link between systemic metabolism and prostate differentiation and growth.^[@bib19]^ There are two isoforms of PPAR*γ* with the longer PPAR*γ*2 isoform using an alternate transcription start site containing a 30-amino acid N-terminal extension.

Our goal in this study was to garner a fundamental molecular and cellular understanding of the role of PPAR*γ* in mediating metabolic control of prostatic differentiation. Because of the importance of individual PPAR*γ* isoforms in systemic metabolism and our previous work implicating PPAR*γ* in prostate epithelial growth and differentiation, we chose to examine the potential roles of individual PPAR*γ* isoforms in mediating nutrient metabolism in the prostate, which has not been performed in any tissue. A prostatic epithelial cell line (mPrE-PPAR*γ*KO) restored with either PPAR*γ*1 or PPAR*γ*2 isoform was used to determine how each isoform might contribute to prostatic metabolism, differentiation and disease. We show, using *in vitro* analysis, lipidomics and *in vivo* animal models that PPAR*γ* isoforms control overlapping and distinct metabolic programs in prostate epithelia that lead to functional changes in glucose and lipid metabolism and that these changes are coordinate with reduced lipogenesis, increased *β*-oxidation and markers of basal and luminal epithelial differentiation. Furthermore, we show in animals that prostate differentiation is oppositely affected after chronic treatment with a TZD *versus* high-fat diet (HFD) through disparate regulation of PPAR*γ*-and its downstream genes. These data suggest, as in other tissues, that PPAR*γ* agonization may directly or indirectly modulate the nutritional supply of glucose and lipids for prostate metabolism and differentiation.

Results
=======

Restoration of PPARγ2, but not PPARγ1, reverses PPARγKO-induced mouse prostatic carcinogenesis
----------------------------------------------------------------------------------------------

Alternative transcription start sites and splicing produce two PPAR*γ* isoforms, so only the longer PPAR*γ*2 isoform can be knocked out individually.^[@bib20]^ In order to study the independent functions of PPAR*γ*1 and -*γ*2 isoforms on prostate metabolism and differentiation, we developed a prostate epithelial cell line (mPrE-PPAR*γ*KO) with genetic knockout (KO) of both PPAR*γ*1 and -*γ*2 isoforms from an adult PB-Cre4 ^*tg/0*^/ PPAR*γ*^*flox/flox*^ double-transgenic male mouse.^[@bib17]^ We then restored mPrE-*γ*KO cells with mouse PPAR*γ*1 cDNA (+PPAR*γ*1), PPAR*γ*2 cDNA (+PPAR*γ*2) or an empty vector (+EV) as control, respectively, to create an isogenic series of cell lines for genetic and functional comparisons (see Materials and Methods).

In order to determine the effects of PPAR*γ* isoforms on tissue morphogenesis *in vivo*, mPrE-*γ*KO and restored cell lines were each recombined with inductive 18-day fetal rat urogenital mesenchyme (UGM) and grafted into the kidney capsule for 2 months ([Figures 1a--c](#fig1){ref-type="fig"}). Control mPrE-*γ*KO+EV cells (empty vector-transfected) regenerated high-grade mouse prostatic intraepithelial neoplasia (HGPIN) (Jiang *et al.*^[@bib17]^; [Figure 1a](#fig1){ref-type="fig"}) with predominantly Ck8/Ck18^+^ luminal epithelial glands and few Ck14^+^ basal cells ([Figure 1d](#fig1){ref-type="fig"}). Upon restoration with PPAR*γ*1, large areas of Ck8/18^++^/Ck14^−^ middle or highly differentiated adenocarcinoma were observed in +PPAR*γ*1 tissue recombinants ([Figure 1b](#fig1){ref-type="fig"}, black star, [Figure 1e](#fig1){ref-type="fig"}), but large fluid-filled cysts were also formed ([Figure 1b](#fig1){ref-type="fig"}, white star). PPAR*γ*2 restoration resulted in the regeneration of Ck8/18^+^/Ck14^++^ acini that resembled developing prostate glands without evidence of tumor formation ([Figures 1c and f](#fig1){ref-type="fig"}). Furthermore, androgen receptor (AR) expression was demonstrated in regenerated tissues by immunohistochemical staining using +EV or +PPAR*γ*2 cells, but not with +PPAR*γ*1 cells ([Figures 1g--i](#fig1){ref-type="fig"}). These data indicate that restoration of PPAR*γ*2 isoform, but not PPAR*γ*1 isoform, reverses PPAR*γ*-deficient mouse prostatic carcinogenesis through an increase in Ck14^+^ basal cells.

PPARγ isoforms 1 and 2 differentially regulate mouse prostate benign epithelial cell differentiation as well as luminal AR expression and function
--------------------------------------------------------------------------------------------------------------------------------------------------

In order to confirm the *in vivo* restoration of basal and luminal differentiation by PPAR*γ*2 expression shown in [Figure 1](#fig1){ref-type="fig"}, protein expression in mPrE-*γ*KO +EV, +PPAR*γ*1 and +PPAR*γ*2 cells was examined by western blot, which revealed increases in both Ck14 and AR upon expression of PPAR*γ*2 ([Figure 2a](#fig2){ref-type="fig"}). To determine whether PPAR*γ* isoform expression increased the differentiation of basal cells *in vitro*, each mPrE-*γ*KO cell line was double stained in culture for PPAR*γ* and Ck14 ([Figure 2b](#fig2){ref-type="fig"}(i--iii)). Results demonstrated that although PPAR*γ* expression in +PPAR*γ*1 cells was increased 14% *versus* +EV cells, this resulted in an insignificant change in Ck14 expression ([Figure 2b](#fig2){ref-type="fig"} (ii *versus* iii)). Alternatively, and consistent with regeneration experiments *in vivo* ([Figure 1f](#fig1){ref-type="fig"}), PPAR*γ*2 restoration resulted in a 15% increase in PPAR*γ*^+^ cells as well as a 15% increase in Ck14^+^ cells ([Figure 2b](#fig2){ref-type="fig"}(iii), quantified in [Figure 2c](#fig2){ref-type="fig"}). Interestingly, only 6--9% of the PPAR*γ*^+^ cells had overlapping Ck14 expression, suggesting a potential paracrine regulation of basal cell differentiation. To determine whether the increase in basal cells also resulted in increase luminal differentiation, cells were treated with dihydrotestosterone (DHT) and co-stained for AR and CK14 ([Figure 2b](#fig2){ref-type="fig"}(iv-vi)). In PPAR*γ*2-rescued cells, cells adjacent to PPAR*γ*^+^ cells were observed to have nuclear AR localization ([Figure 2b](#fig2){ref-type="fig"}(vi), arrowhead). In contrast, fewer cells were found with nuclear AR localization in +EV or +PPAR*γ*1 cells treated with DHT ([Figure 2b](#fig2){ref-type="fig"}(iv *versus* v)). To confirm increased AR responsiveness, an androgen response element (ARE)-luciferase construct was transfected in each cell line, which demonstrated that +PPAR*γ*2 cells significantly increased AR responsiveness 3-fold, while +PPAR*γ*1 cells had no response and mPrE-*γ*KO+EV cells had a 1.8-fold increase ([Figure 2d](#fig2){ref-type="fig"}). The results showed restoration of PPAR*γ*2 rescues and drives mouse prostate benign epithelial cell differentiation associated with AR activation.

PPARγ isoforms 1 and 2 regulate both overlapping and distinct metabolic networks
--------------------------------------------------------------------------------

In order to determine the potential molecular disparity between PPAR*γ*1- and PPAR*γ*2-driven epithelial differentiation, microarrays were performed on mPrE-PPAR*γ*KO+EV *versus* +PPAR*γ*1 or +PPAR*γ*2 cells. As outlined in [Figure 3a](#fig3){ref-type="fig"}, +EV cells minus/plus Rosiglitazone (Rosi) were examined to eliminate PPAR*γ*-independent effects of Rosi ([Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}). These independent effects were subtracted from results generated from comparison of +EV *versus* +PPAR*γ*1 and +EV *versus* +PPAR*γ*2 to identify PPAR*γ*-specific effects of Rosi. Using INGENUITY software (Redwood City, CA, USA) and the significance analysis of microarray (SAM) test for significance, [Figure 3b](#fig3){ref-type="fig"} displays the top networks regulated by PPAR*γ* isoforms in prostate epithelial cells. Individual genes regulated by PPAR*γ*1 and PPAR*γ*2 (top 10 up and down-regulated genes shown in [Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}) included numerous focus molecules with functions related to amino acid, carbohydrate and lipid metabolism, drug metabolism and cellular detoxification as well as inflammation and immunity.

Restoration of PPARγ1 or -γ2 isoforms reduces lipogenesis/oxidative stress
--------------------------------------------------------------------------

Microarray data analysis of PPAR*γ* isoform-regulated genes showed a strong upregulation of genes involved in fatty acid metabolism, which has been shown to reduce *de novo* lipogenesis in some tissues;^[@bib21]^ however, the influence of fatty acid metabolism on prostate differentiation has not been examined. Accordingly, western blotting revealed that PPAR*γ*1 or PPAR*γ*2 expression resulted in a decrease in lipogenic pathways (Akt, mTOR, Fasn, Acc) and oxidative stress (Cox-2) ([Figure 4a](#fig4){ref-type="fig"}). Flow cytometry of dihydroethidium-stained cell lines confirmed a significant reduction in reactive oxygen species (ROS) upon expression of PPAR*γ* isoforms ([Figure 4b](#fig4){ref-type="fig"}). These data suggest that paracrine PPAR*γ* expression satisfies the endogenous lipid needs, thereby negating the need for *de novo* lipogenesis.

To confirm candidate genes identified by INGENUITY software analysis, qRT-PCR plates were custom-designed for analysis of PPAR*γ*-restored cell lines. Results showed that both PPAR*γ* isoforms regulated genes involved in metabolism ([Table 1](#tbl1){ref-type="table"}, Section I), including the modification (*Elovl4, Scd1*), transport (*Cd36, Lpl, Fabp4*) and *β*-oxidation (*Acsf2, Lipa, Acot1*) of fatty acids. In addition, multiple genes involved in detoxification were upregulated ([Table 1](#tbl1){ref-type="table"}, Section II), notably including *Cox-2*, further confirming the decrease in ROS shown in [Figure 4b](#fig4){ref-type="fig"}. Finally, multiple markers of differentiation ([Table 1](#tbl1){ref-type="table"}, Section III) were upregulated, notably including regulation of basal cell (*Trp63, Ck14*) and luminal cell (*Pbsn, AR, PTEN*) markers by PPAR*γ*2, confirming the changes shown in [Figure 1](#fig1){ref-type="fig"}. These data suggest that increased fatty acid import results in a reduction in lipogenesis and oxidative stress.

PPAR*γ* isoforms differentially regulate glucose and fatty acid metabolism
--------------------------------------------------------------------------

One of the most interesting examples of isoform-specific changes in fatty acid modification genes was the differential regulation of *Scd1*, which was upregulated by PPAR*γ*2 but downregulated by PPAR*γ*1 ([Table 1](#tbl1){ref-type="table"}, Section I). Scd1 is an ER-resident fatty acid desaturase strongly induced by dietary saturated fat and responsible for the production of monounsaturated fatty acids (MUFAs) from 12 to 19 carbon saturated fatty acids, and has been implicated in numerous metabolic diseases. MUFAs are the preferred substrates in the synthesis of major lipid classes including phospholipids, cholesterol esters, wax esters and triglycerides.^[@bib22],\ [@bib23]^

When various lipid classes were analyzed (phospholipids, diglycerides, triglycerides and cholesterol esters) in PPAR*γ*1 and -*γ*2-restored mPrE-*γ*KO cells, we found that not only were total triglyceride stearic acid levels increased, but also that the PPAR*γ*1-mediated Scd1 decrease resulted in a significantly increased abundance of stearic acid and decreased abundance of oleic acid ([Figure 4c](#fig4){ref-type="fig"}). As shown above, PPAR*γ*1 expression also failed to induce prostatic differentiation ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), indicating that an increased availability of MUFAs through PPAR*γ*2-mediated Scd1 expression may be beneficial for normal prostate epithelial differentiation.

As for other PPARs,^[@bib21]^ we found using qRT-PCR that PPAR*γ*1 and -*γ*2 also regulated glucose metabolism genes, notably increasing *Pdk4* expression ([Table 1](#tbl1){ref-type="table"}). Pdk4 phosphorylates and inactivates pyruvate dehydrogenase, resulting in the shunting of pyruvate toward lactate production rather than entry in the mitochondrial tricarboxylic acid (TCA) cycle. In tissues such as muscle, metabolic switching from glucose to fatty acid oxidation is mediated by increased Pdk4 expression.^[@bib24]^ To determine whether increased Pdk4 expression resulted in altered glucose/lactate flux, we collected conditioned media from mPrE-PPAR*γ*KO and the isoform-restored cells over a 4-day period. Results demonstrated a decrease in glucose flux in PPAR*γ*-restored cells ([Figure 4d](#fig4){ref-type="fig"}), coordinate with the level of Pdk4 expression ([Table 1](#tbl1){ref-type="table"}), with PPAR*γ*1 mediating the strongest upregulation of Pdk4 and decrease in glucose consumption. A significant increase in lactate production was observed in PPAR*γ*2-restored cells, indicating increased glycolytic metabolism. Furthermore, the increased glucose/lactate ratios observed in both PPAR*γ*-restored cells points to a clear shift away from glucose oxidation in the TCA cycle in favor of lactate production. Measurement of the IC50 of the glucose analog and oxidation inhibitor 2-deoxy-𝒟-glucose (2DG) showed that mPrE-PPAR*γ*KO+EV cells were significantly more sensitive to inhibition of glucose metabolism than their PPAR*γ*-restored counterparts ([Figure 4e](#fig4){ref-type="fig"}), which are more likely to rely on fatty acid oxidation according to genes shown in [Table 1](#tbl1){ref-type="table"}.

These data demonstrate that although restoration of either PPAR*γ* isoform in PPAR*γ* KO HGPIN cells decreases *de novo* lipogenesis and oxidative stress, only PPAR*γ*2-regulated genes induce a metabolic switch for induction of a prostatic differentiation program, potentially through disparate regulation of Scd1.

TZD or HFD treatment drives opposing effects on mouse prostate metabolism and differentiation *in vivo*
-------------------------------------------------------------------------------------------------------

PPAR*γ* has been hypothesized to provide a metabolic link between obesity and tissue dysfunction.^[@bib13]^ In order to determine whether TZDs or obesity affect PPAR*γ*-mediated prostatic differentiation *in vivo*, we fed male mice a Western diet or Rosiglitazone chow for 6 months and examined their prostates for changes in morphology ([Figure 5](#fig5){ref-type="fig"}) and PPAR*γ*-regulated genes ([Table 2](#tbl2){ref-type="table"}). Significant increases in overall animal weight were detected following HFD treatment only ([Figure 5a](#fig5){ref-type="fig"}). Notable increases in smooth muscle density were observed with TZD treatment ([Figure 5d](#fig5){ref-type="fig"}), with little epithelial hyperplasia. In addition, intra-muscular adipocytes were also highly enriched in TZD-treated animals ([Figure 5d](#fig5){ref-type="fig"}, star), which made clean dissection for RNA analysis of prostate-specific genes extremely difficult. This is consistent with the deposition of intramuscular adipocytes in skeletal muscle of TZD-treated human subjects.^[@bib25]^ Although PPAR*γ*2 is thought of as an adipose-specific gene, we were able to demonstrate using a PPAR*γ*2-specific antibody that it is also expressed sporadically in mouse prostate luminal epithelia ([Figure 5f](#fig5){ref-type="fig"}) as well as throughout the smooth muscle ([Figure 5b](#fig5){ref-type="fig"}).

As shown in [Table 2](#tbl2){ref-type="table"}, large increases in PPAR*γ*-regulated genes were observed in TZD-treated animals. Given the increase in intraprostatic adipocytes after TZD treatment, it was unclear whether these changes were regulated in adipocytes or prostate. Therefore, immunohistochemistry was performed on metabolic proteins including Scd1, Lpl, Cd36, Fabp4 and Pdk4. Although ectopic PPAR*γ* expression was able to regulate some of the fatty acid metabolism genes *in vitro* ([Table 1](#tbl1){ref-type="table"}), immunoreactivity for Fabp4 ([Supplementary Figure 1c](#sup1){ref-type="supplementary-material"}), Lpl and Scd1 was low in mouse prostate and high in adjacent adipocytes, likely reflecting the strong increases in RNA expression shown in [Table 2](#tbl2){ref-type="table"}, Section II. However, immunoreactivity for Cd36 (expressed in epithelia and stroma, [Supplementary Figure 1b](#sup1){ref-type="supplementary-material"}) and Pdk4 (expressed in epithelia, [Figure 5l--n](#fig5){ref-type="fig"}) were strong, suggesting that these genes might be important in directly mediating the metabolism and differentiation of prostate, *versus* Fabp4 and Lpl, which may indirectly mediate prostate differentiation through adjacent adipocyte fatty acid metabolism.

As PPAR*γ*-regulated genes were so drastically affected in TZD-treated animals, epididymal white adipose tissue (eWAT) gene expression was also examined by qRT-PCR under normal conditions or TZD treatment and was directly compared with that of prostate ([Table 2](#tbl2){ref-type="table"}, row 1 *versus* row 2). Results are compartmentalized into genes predominantly regulated by TZD in either eWAT (I) or prostate (II) or both (III). Contrary to common perceptions of both adipose and prostate, total PPAR*γ* levels (isoforms were not discriminated by qRT-PCR) were higher in prostate than eWAT under normal feeding conditions and AR levels were equivalently expressed (contamination by adipocytes in prostates of animals fed regular chow was minimal). However, under TZD treatment, *AR* (and *probasin*) levels increased in prostate and not eWAT. Notably, PPAR*γ*2 is allostatically induced in adipose under HFD,^[@bib26]^ which could explain the lower levels of total PPAR*γ* in lean mouse eWAT *versus* prostate. Recent evidence of the molecular signature of various adipose depots could also explain the difference in PPAR*γ*-regulated genes in eWAT *versus* the intramuscular adipose of TZD-treated prostate,^[@bib27]^ which may indicate the expansion of highly metabolic brown adipose shown previously to be regulated by TZDs.^[@bib28]^

Other notable differences between prostate and eWAT gene expression patterns included numerous oxidative stress genes (*Cat, Gsta2, Sirt5, Nox1, Nfkb2*) and the triglyceride-synthesizing enzyme *Dgat2*, which were highly enriched in adipose *versus* prostate. However, a number of fatty acid metabolism (*Acsf2, Adipor1, Cd36, Lpl*) and differentiation (*AR, probasin*) genes were equally high in prostate, including the glucose oxidation inhibitor, *Pdk4*, which suggests that the differentiation induced by PPAR*γ* expression shown here may represent a metabolically regulated program of prostatic differentiation *in vivo*.

Given the regulation of prostate differentiation by PPAR*γ*2 in mouse, we also wanted to confirm the expression of PPAR*γ*2 and some of its downstream-regulated genes in human prostate tissue. [Figure 6a](#fig6){ref-type="fig"} shows that PPAR*γ*2 is highly enriched in prostate smooth muscle and that Scd1 (upregulated by PPAR*γ*2 expression *in vitro*) is highly enriched in prostate basal cells ([Figure 6b](#fig6){ref-type="fig"}). Furthermore, CD36 was expressed in both epithelia and smooth muscle ([Figure 6c](#fig6){ref-type="fig"}), whereas PDK4 was expressed predominantly in epithelia ([Figure 6d](#fig6){ref-type="fig"}). The compartmentalization of cellular glucose and fatty acid metabolism ([Figure 6e](#fig6){ref-type="fig"}) suggests a model of stromal--epithelial, as well as basal--luminal interactions whose disruption by systemic metabolic disease may adversely affect the health and differentiation of prostate ([Figure 6f](#fig6){ref-type="fig"}). These results suggest that PPAR*γ* is a major metabolic regulator in the control of mouse and human prostate differentiation.

Discussion
==========

A recent study of the global prevalence of glycemia and diabetes demonstrated an increase from 153 million affected individuals in 1980 to 347 million in 2008,^[@bib29]^ which, according to epidemiological correlations, will likely have a major direct impact on prostate disease incidence. Upon maximal lipid storage capacity of white adipose tissue (WAT), peripheral tissues begin to store lipid in excess of their natural oxidative or storage capacity resulting in lipotoxicity, inflammation and eventually insulin resistance.^[@bib30]^ Recent evidence squarely positions prostatic diseases as sequelae of systemic metabolic dysfunction, including hyperinsulinemia, hyperglycemia and hypercholesterolemia^[@bib31]^; however, the underlying etiologies of such susceptibilities remain unknown largely because of the absence of a molecular understanding of the basic metabolic machinery governing prostatic function.

Here, we demonstrate that expression of PPAR*γ*2 drives benign prostate epithelial cell differentiation. In mouse prostate PPAR*γ*2 was expressed in both smooth muscle and epithelium ([Figures 5b and f](#fig5){ref-type="fig"}), whereas in human prostate PPAR*γ*2 expression seems to be restricted to smooth muscle ([Figure 6a](#fig6){ref-type="fig"}). Stromal--epithelial interactions have long been recognized to have a role in prostate differentiation,^[@bib32]^ but the underlying mechanisms remain elusive. These data suggest that paracrine fatty acid metabolism may drive epithelial differentiation, resulting in decreased glucose metabolism, oxidative stress and lipogenesis ([Figure 4](#fig4){ref-type="fig"}).

PPAR*γ* has been shown to regulate the balance between glucose and lipid oxidation in a tissue-specific manner.^[@bib33]^ Here, we show that TZD treatment upregulated markers of prostatic differentiation in correlation with an increase in highly metabolic smooth muscle and intramuscular adipose ([Figure 5](#fig5){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}), which also correlated with the decreased glucose flux and lipogenesis shown in PPAR*γ*-restored cells *in vitro* ([Figure 2](#fig2){ref-type="fig"}).

The isoform-specific effects of PPAR*γ* have not been directly compared in any tissue. One of the most interesting genes differentially regulated by PPAR*γ* isoforms in prostate was the fatty acid desaturase Scd1. Systemic deletion of *Scd1* provides protection against obesity due to reduced fatty acid and triglyceride synthesis as well as increased oxidation.^[@bib22],\ [@bib23]^ In contrast to other tissues, SCD1 expression is high in human prostate epithelia, but its expression and role in prostate cancer has been debated.^[@bib34],\ [@bib35]^ Moreover, PPAR*γ*2 upregulated Scd1 expression and drove basal cell differentiation ([Figure 2](#fig2){ref-type="fig"}), and SCD1 was shown to be predominantly restricted to the basal cell compartment of normal human prostate ([Figure 6b](#fig6){ref-type="fig"}) whereas PPAR*γ*2 was predominantly expressed in smooth muscle ([Figure 6a](#fig6){ref-type="fig"}). As modeled in [Figure 6f](#fig6){ref-type="fig"}, these data led us to hypothesize that PPAR*γ*2-mediated import and oxidation of fatty acids may dictate prostate basal cell differentiation through increased SCD1.

Tissue-specific effects of PPAR*γ* agonization have demonstrated that the upregulation of liver fatty acid and sterol synthesis in HFD-fed rats could be reversed by PPAR*γ* agonists, whereas the same HFD stimulated PPAR*γ* downregulation and lipogenesis in muscle.^[@bib13]^ Concordant with studies demonstrating positive effects of TZDs on HFD mouse prostates,^[@bib36],\ [@bib37]^ we demonstrated here that chronic HFD treatment resulted in decreased androgen signaling and low-grade PIN, coordinate with decreased PPAR*γ* signaling ([Figure 5](#fig5){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). These data suggest that an allostatic response to downregulate fatty acid import and metabolism may negatively affect prostate differentiation through metabolic switching.

Cells access and metabolize fatty acids through the activities of lipases (e.g., Lpl, Lipa), transporters (e.g., Fabp4, Cd36) and enzymes (acyl-coa synthetases, thioesterases), which supply the cell with acetyl coenzyme A (acetyl-CoA) for eventual entry into mitochondria for energy production. Alternatively, acetyl-CoA can be used as a building block for MUFA production (Scd1) and subsequently converted into triglycerides, cholesterol esters and phospholipids ([Figure 6e](#fig6){ref-type="fig"}). The therapeutic efficacy of targeting fatty acid metabolism (synthesis, modification, transport and oxidation) has had some success, but off-target effects have limited their broad usage.^[@bib10]^ Similarly, more selective drugs targeting PPAR*γ* and Scd1 promising fewer side effects are being pursued.^[@bib22],\ [@bib38]^ Future studies must be able to link changes in systemic metabolism to local metabolic changes in prostate, which mandates a deeper understanding of the fundamental metabolic infrastructure regulating prostatic differentiation and what allostatic changes may occur in response to systemic metabolic stress. The data presented here suggest that a microenvironment of PPAR*γ*2-mediated fatty acid metabolism by stroma or adipose may drive prostatic epithelial differentiation; however, under conditions of diabetes and obesity fatty acid supply may become saturated, leading to inflammation and hyperplasia in prostate disease ([Figure 6f](#fig6){ref-type="fig"}).

Materials and Methods
=====================

Generation of cell lines, microarray studies and qRT-PCR
--------------------------------------------------------

mPrE-PPAR*γ*KO cells were spontaneously immortalized from an adult PBCre4^*tg/0*^/PPAR*γ*^*flox/flox*^ double-transgenic male mouse.^[@bib17]^ The pQCXIP-empty vector, mouse PPAR*γ*1 or PPAR*γ*2 wild-type full-length cDNA (gifts from Drs. Y Eugene Chen and Jifeng Zhang, University of Michigan Medical Center) were stably transfected into the mPrE-PPAR*γγ*KO cells to generate mPrE-PPAR*γγ*KO+EV, mPrE-PPAR*γ*KO+PPAR*γ*1 or mPrE-PPAR*γ*KO+PPAR*γ*2 cell line, respectively.^[@bib17]^

Microarray and network analyses and qRT-PCR validation
------------------------------------------------------

RNA was isolated with Trizol (Ambion, Austin, TX, USA) and reverse transcribed by RNeasy columns (Qiagen, Valencia, CA, USA) followed by reverse transcription (Qiagen) for hybridization on mouse Genechip St. 1.0 microarrays using triplicate samples from each cell line treated with 5 *μ*M Rosiglitazone (Rosi) (Cayman Chemical, Ann Arbor, MI, USA) as well as mPrE-PPAR*γ*KO+EV without Rosi. PPAR*γ*-independent effects of Rosi generated in mPrE-PPAR*γ*KO+EV cells were subtracted from results comparing mPrE-PPAR*γ*KO+EV *versus* PPAR*γ*-restored cells. SAM was used to stringently select (FDR\<0.05) statistically significant genes. Both SAM and unsupervised hierarchical clustering analysis were carried out using TIGR MeV program. Their possible networks and canonic pathways were identified using INGENUITY software ([https://apps.ingenuity.com](http://https://apps.ingenuity.com)). Custom qRT-PCR plates manufactured by SABiosciences (Valencia, CA, USA) were designed to analyze selected PPAR*γ*-regulated genes in Rosi-treated mPrE-PPAR*γ*KO+EV, mPrE-PPAR*γ*KO+PPAR*γ*1 and mPrE-PPAR*γ*KO+PPAR*γ*2 cell lines in triplicate. Results were analyzed using SABiosciences qRT-PCR analysis software (SABiosciences.com) and represented fold changes based on ΔΔ*C*~t~ analysis.

Detection of ROS
----------------

Each cell line was grown to confluence, trypsinized, washed and incubated with 1 *μ*M Dihydroethidium (Life Technologies, Carslbad, CA, USA) for 15 min followed by three washes in PBS. Flow cytometry was then performed and results represent the average mean intensity (*N*=3). Statistical analysis was performed by GraphPad Prism software (La Jolla, CA, USA) using Student\'s unpaired *t* test.

Fatty acid profile (TLC/MS)
---------------------------

Lipid class separation and fatty acid identification of cell lines were performed by the Vanderbilt Hormone Assay and Analytical Services Core (<http://hormone.mc.vanderbilt.edu/>). Briefly, the Folch method of lipid extraction^[@bib39]^ was followed by thin layer chromatography (TLC) was used to isolate triglycerides. Fatty acid analysis was performed by mass spectrometry (MS) with internal standards. Total triglycerides were normalized to protein concentration as determined by the Lowry method. Statistical analysis was performed on triplicate samples by GraphPad Prism software using one way ANOVA test.

Luciferase assay
----------------

Cells were grown to 70% confluency in 12-well culture plates and cotransfected with pRL-null (0.16 *μ*g/well) and ARR2PB-Luciferase (1.44 *μ*g/well) using 4 *μ*l Lipofectamine 2000 in OptiMEM (Invitrogen, Grand Island, NY, USA). After 24 h transfection, media was replaced with 10% charcoal-stripped FBS in DMEM plus or minus 10^−8^ M DHT and incubated for 24 h. At this time, cells were lysed and dual luciferase activity measured using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) on a Turner Biosystems 20/20^n^ luminometer (Promega). Results were statistically analyzed by Student\'s unpaired *t* test (*N*=3) using GraphPad Prism.

Western blot
------------

Western blotting was performed as described previously.^[@bib17]^ Briefly, 30 *μ*g protein was loaded on 10% SDS acrylamide gels (Life Technologies) and transferred onto PVDF membranes (Millipore, Temecula, CA, USA). The following antibodies were used for detection: mTOR, phospho-mTOR, PTEN, ACC and AKT, phospho-AKT (S473) were from Cell Signaling (1 : 1000, Danvers, MA, USA), Cox-2 (1 : 500, Millipore), AR and PPAR*γ* (1 : 250, Santa Cruz Biotechnology, Santa Cruz, CA, USA), FASN (1 : 1000, GeneTex, Irvine, CA, USA), Gapdh (1 : 1000, Abcam, Cambridge, MA, USA) and Ck14 (1 : 1000, Vector Labs, Burlingame, CA, USA). Blots were then incubated with secondary antibodies (1 : 1000, anti-mouse, anti-rabbit from GE Healthcare, Buckinghamshire, UK) for 45 min in 5% milk in TBST, washed and developed with Western Lightning Plus-ECL (Perkin Elmer, Waltham, MA, USA).

ICC/IHC
-------

ICC/IHC was performed as described previously.^[@bib17]^ Briefly, cells were cultured on glass chamber slides (LabTek II, Naperville, IL, USA), washed with PBS, fixed in 4% PFA for 15 min, blocked in 12% BSA for 1 h and incubated with primary antibodies (1 : 25 PPAR*γ*, Santa Cruz; 1 : 50 CK14, Vector Labs; 1 : 100 AR, Santa Cruz; 1 : 500 Ck8/18, Fitzgerald, Acton, MA, USA) in 12% BSA at 4°C overnight followed by incubation with a fluorescent secondary antibody (1 : 1000, Molecular Probes, Eugene, OR, USA) for 45 min at 37°C. Cells were counterstained and mounted with Dapi Vectashield (Vector Labs) and images were taken on a Zeiss Axioplan microscope. Tissues harvested from grafted (kidney capsule) or TZD- or HFD-treated mice (epididymal WAT, prostate) were fixed in 10% formalin at 4°C overnight, paraffin embedded and then 5 *μ*M sections cut for immunohistochemistry. Slides were deparaffinized, rehydrated and endogenous peroxidases blocked with 2% H~2~O~2~ in methanol. Following citrate retrieval and blocking with 5% goat serum, slides were incubated at 4°C overnight with the following antibodies: AR (1 : 200, Santa Cruz), PPAR*γ*2 (1 : 200, Abcam), smooth muscle actin (1 : 2000 Invitrogen), Ck14 (1 : 100), CK18 (1 : 500), PDK4 (1 : 500, ProteinTech, Chicago, IL, USA). Secondary antibodies for IHC were from Dako (Carpinteria, CA, USA) and used at 1 : 200 dilution. Secondary antibodies for IF (1 : 1000, Molecular Probes) were incubated for 45 min followed by mounting with DAPI Vectashield.

Tissue recombination
--------------------

Tissue recombination was performed as described previously.^[@bib17]^ Briefly, 400 K of each mPrE-PPAR*γ*KO-related cell lines were recombined with 18-day fetal rat UGM and grafted in collagen into the kidney capsule of male SCID mice for 2 months. Grafts were harvested and fixed in formalin for morphologic and immunohistochemical analysis.

Glucose/lactate measurements
----------------------------

Extracellular uptake and excretion rates were determined in triplicate growth experiments. Eight separate 48-well tissue culture plates were seeded at a density of 20 K cells. One plate was sampled every 10--14 h, whereby the conditioned medium was removed and frozen at −80°C. The remaining cells on the plate were stained with crystal violet for assessment of cell number. Concentrations of medium glucose and lactate were determined using a YSI 2300 Stat Plus Glucose and Lactate Analyzer (YSI, Yellow Springs, OH, USA). Cell-specific rates of glucose consumption and lactate production were determined by regression analysis using the method of Glacken *et al.*^[@bib40]^

Animal experiments
------------------

To examine the effects of TZD or HFD regimen on prostate gene expression *in vivo*, control, Rosiglitazone chow (0.188% Avandia) or Western diet chow (16% protein, 40% carbohydrate, 40% fat, 0.15% cholesterol) (Test Diets, Richmond, IN, USA) were fed to male C57B mice for 6 months at which time the animals were weighed (Student\'s unpaired *t* test for statistical analysis) and tissues removed for formalin fixation and storage at −80°C for later RNA extraction. Because of the extreme density of adipose directly surrounding the prostate of both TZD- and HFD-fed animals, care was taken to dissect away as much as possible. WAT was taken from the epididymal fat pad. RNA was extracted and cDNA synthesized for qRT-PCR on custom-designed plates (Qiagen) using an ABI 7900HT real-time PCR machine with a standard block according to the manufacturer\'s instructions. Results represent triplicate experiments and fold changes were calculated as described above. *P* values were mostly insignificant, given the contamination by intramuscular adipocytes and were therefore not shown.

All microarray experiments were performed in the Vanderbilt Genome Sciences Resource. The Vanderbilt Genome Sciences Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485), the Vanderbilt Digestive Disease Center (P30 DK58404) and the Vanderbilt Vision Center (P30 EY08126). This work was supported by a Department of Defense Prostate Cancer Training Award W81XWH-07-1-0479 to DWS, P20 DK090874 and 2R01 DK067049 to SWH, and R21 CA155964 to JDY. All fatty acid analyses were performed by the Vanderbilt Hormone Assay and Analytical Services Core. We thank Drs. Robert Matusik and David Degraff for helpful discussions and manuscript editing.

acetyl-CoA

:   acetyl coenzyme A

AR

:   androgen receptor

ARE

:   androgen response element

BPH

:   benign prostatic hyperplasia

DHT

:   dihydrotestosterone

eWAT

:   epididymal white adipose tissue

HFD

:   high-fat diet

MetS

:   metabolic syndrome

mPrE-PPAR*γ* KO (mPrE-*γ*KO)

:   a PPAR*γ* knockout mouse prostate epithelial cell line spontaneously immortalized from an adult PBCre~4~^*tg/0*^/PPAR*γ*^*flox/flox*^ mouse prostate

mPrE-PPAR*γ*KO+PPAR*γ*1 (+PPAR*γ*1 or +*γ*1)

:   mPrE-*γ*KO overexpressing mouse PPAR*γ*1 WT full-length cDNA

mPrE-PPAR*γ*KO+PPAR*γ*2 (+PPAR*γ*2 or +*γ*2)

:   mPrE-*γ*KO overexpressing mouse PPAR*γ*2 WT full-length cDNA

mPrE-PPAR*γ*KO+empty vector (+EV)

:   mPrE-*γ*KO retrovirally transduced using a control empty vector

MUFAs

:   monounsaturated fatty acids

KO

:   knockout

PCa

:   prostate cancer or prostate carcinoma

PIN

:   prostatic intraepithelial neoplasia

PPAR*γ*

:   peroxisome proliferator-activated receptor gamma

ROS

:   reactive oxygen species

TCA

:   tricarboxylic acid

TZDs

:   thiazolidinediones

UGM

:   urogenital mesenchyme
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###### 
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![Restoration of PPAR*γ*2, but not PPAR*γ*1, reverses PPAR*γ* KO-induced mouse prostate carcinogenesis. mPrE-PPAR*γ*KO+EV, +PPAR*γ*1 or +PPAR*γ*2 cell lines were recombined with inductive rat UGM and grafted under the kidney capsule for 2 months (*N*=3 each). Histological analysis revealed regeneration of Ck14^+^/Ck18^+^/AR^+^ HGPIN in mPrE-PPAR*γ* PPAR*γ*KO+EV grafts (**a, d** and **g**). Restoration of PPAR*γ*1 resulted in a mixture of fluid-filled cysts (black star) and CK14^−^/Ck18^+^/AR^−^ middle to highly differentiated adenocarcinoma (white star) (**b, e** and **h**). Restoration of PPAR*γ*2 resulted in regeneration of Ck14^++^/Ck18^+^/AR^+^ benign acinus formation without any tumors (**c, f** and **i**)](cddis201299f1){#fig1}

![PPAR*γ* isoforms 1 and 2 differentially regulate prostate basal differentiation as well as luminal AR expression and function. (**a**) Western blot analysis of mPrE PPAR*γ*KO +EV, +PPAR*γ*1 or +PPAR*γ*2 cells shows dual increase in Ck14 and AR in mPrE PPAR*γ*KO +PPAR*γ*2 cells compared with +EV or +PPAR*γ*1 cells. (**b**) ICC of PPAR*γ* (red) and Ck14 (green) in mPrE-PPAR*γ*KO+EV (i), +PPAR*γ*1 (ii) or +PPAR*γ*2 (iii) cells in culture shows an increase in Ck14^+^ cells in +PPAR*γ*2, but not +PPAR*γ*1 cells. ICC for AR and Ck14 in mPrE-PPAR*γ*KO+EV (iv), +PPAR*γ*1 (v) or +PPAR*γ*2 (vi) cells treated with DHT shows cytoplasmic AR in most mPrE-PPAR*γ*KO+EV or +PPAR*γ*1 cells, whereas +PPAR*γ*2 cells displayed increased nuclear AR immunoreactivity in cells adjacent to Ck14^+^ cells. (**c**) Quantitation of PPAR*γ* immunoreactivity shows a significant increase of 15% for PPAR*γ*-restored cells compared with +EV cells, whereas only PPAR*γ*2-restored cells showed a significant 15% increase in Ck14 immunoreactivity compared with +EV cells. (**d**) Androgen responsiveness was increased three-fold in +PPAR*γ*2 cells compared with +EV cells as measured by ARE-luciferase (*N*=3). \**P* value\<0.05](cddis201299f2){#fig2}

![Microarray and network analyses of cell lines. (**a**) Schematic of microarray analysis. In order to distinguish PPAR*γ* isoform effects downstream of TZD treatment, PPAR*γ* KO cells (mPrE-PPAR*γ*KO+EV) were treated with Rosiglitazone (Rosi) and these Rosi-independent results (representing 82 genes, see [Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}) were subtracted from the downstream regulation demonstrated in Rosi-treated PPAR*γ*1- (358 differentially regulated genes, see [Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}) or PPAR*γ*2- (400 differentially regulated genes, see [Supplementary Figure 1a](#sup1){ref-type="supplementary-material"}) rescued cells. Further analysis showed that 230 genes were differentially regulated in PPAR*γ*1 *versus* PPAR*γ*2-restored PPAR*γ*2-rescued cells. *N*=3 for each of the four samples. (**b**) Top networks differentially regulated by PPAR*γ* isoforms using INGENUITY](cddis201299f3){#fig3}

![PPAR*γ* isoforms equally decrease *de novo* lipogenesis and oxidative stress, but differentially modulate triglyceride saturation and glucose metabolism. (**a**) Ectopic expression of PPAR*γ*1 or PPAR*γ*2 in mPrE-PPAR*γ*KO cells resulted in decreased activation of lipogenic pathways including Akt, mTOR, Fasn and Acc. In addition, Cox-2 levels were decreased indicative of lower levels of ROS. (**b**) Dihydroethidium staining followed by flow cytometry (N=3) confirmed a decrease in ROS. (**c**) Fatty acid analysis of triglycerides by TLC/MS revealed increased levels and saturation of stearic acid (increased 18 : 0, decreased 18 : 1n9) in PPAR*γ*1-restored cells compared to +EV cells (N=3), consistent with the decreased expression of Scd1 (see [Table 1](#tbl1){ref-type="table"}). (**d**) Glucose/lactate flux analysis in mPrE-PPAR*γ*KO+EV, +PPAR*γ*1 or +PPAR*γ*2 cells over 4 days (2 time points/day) demonstrated significantly decreased glucose uptake in mPrE-PPAR*γ*KO+PPAR*γ*1 cells and significantly increased lactate secretion in mPrE-PPAR*γ*KO+PPAR*γ*2 cells compared to +EV cells. (**e**) IC50 analysis of the glucose oxidation inhibitor 2DG suggested a reliance of mPrE-PPAR*γ*KO+EV cells on glucose in the absence of +PPAR*γ*1 or +PPAR*γ*2 cells, which highly regulate fatty acid transport and metabolism (see [Table 1](#tbl1){ref-type="table"}). \**P* value \<0.05](cddis201299f4){#fig4}

![Administration of TZD or HFD drives opposing effects on mouse prostate metabolism and differentiation *in vivo*. (**a**) Western diet-, but not TZD-fed animals significantly increased total weights by 20 g (*N*=3 each). (**b**) PPAR*γ*2 is coexpressed in prostate smooth muscle. (**c**--**n**) C57B male mice were fed control (**a, f, i** and **l**), Rosiglitazone (**b, g, j** and **m**) or Western diet chow (**e, h, k** and **n**) for 6 months. PPAR*γ*2 levels were similar in prostate epithelia after TZD treatment (**f** *versus* **g**) but decreased in some acini of HFD-treated animals (**h**, star). Intramuscular adipocytes were increased in TZD-treated animals (**g**, star), which also resulted in increased AR expression increased in smooth muscle (**j**, arrow). AR expression was decreased in HFD-treated animals (\* in **k**) similar to qRT-PCR analysis (see [Table 2](#tbl2){ref-type="table"}). PDK4 expression was similar in prostate tissue of TZD-treated animals (**m**, \* indicates adipose) and decreased in HFD-treated animals (**n**) (see [Table 2](#tbl2){ref-type="table"})](cddis201299f5){#fig5}

![PPAR*γ*-regulated genes in human prostate tissues. (**a**) Double staining for PPAR*γ*2 and alpha smooth muscle actin (*α*-SMA) by immunofluorescence revealed colocalization in a subset of smooth muscle. (**b**) SCD1 expression is enriched in prostate basal epithelia by immunohistochemical staining (IHC). (**c**) CD36 is expressed in smooth muscle and epithelia. (**d**) PDK4 is expressed predominantly in the epithelium. (**e**) Cellular model of metabolic genes and functions regulated by PPAR*γ*. (**f**) Tissue interaction model of the potential role of paracrine fatty acid metabolism in regulating prostate differentiation and diseases as comorbidities of diabetes and obesity](cddis201299f6){#fig6}

###### Comparison of gene expression from mPrE-PPAR*γ*KO+EV, +PPAR*γ*1 and +PPAR*γ*2-restored cell lines by qRT-PCR

                                                                                                **+PPAR**γ**1**   **+PPAR**γ**2**           
  ------------------------------ ----------------------------------- -------------------------- ----------------- ----------------- ------- --------
  *I. Metabolic genes*                                                                                                                      
   *Acot1*                       Long chain fatty acid metabolism    Cytoplasm                  19.0              0.09              304.3   \<0.05
   *Acsf2*                       Fatty acid oxidation                Mitochondrion              69.1              \<0.05            109.7   0.10
   *Adipor1*                     Fatty acid oxidation                Plasma membrane            1.7               \<0.05            2.7     \<0.05
   *Cd68*                        Fatty acid transport                Lysosome                   2.1               0.27              11.8    \<0.05
   *Cd36*                        Long chain fatty acid metabolism    Cytoplasm, mitochondrion   3.2               0.09              32.1    \<0.05
   *Dagla*                       Lipolysis                           Plasma membrane            3.5               \<0.05            5.5     0.08
   *Dgat2*                       Triglyceride synthesis              Endoplasmic reticulum      1.4               0.10              3.3     0.08
   *Elovl4*                      Fatty acid elongation               Endoplasmic reticulum      −2.6              0.09              1.3     0.41
   *Fabp4*                       Fatty acid transport                Cytoplasm, nucleus         72.7              \<0.05            220.3   \<0.05
   *Fbp2*                        Carbohydrate metabolism             Cytoplasm                  −3.7              \<0.05            2.1     0.11
   *Fetub*                       Insulin responsiveness              Extracellular              3.2               0.30              2.4     0.13
   *Gls2*                        Glutamine synthesis                 Mitochondrion              −1.3              0.52              −1.2    0.48
   *Glul*                        Glutamine catabolism                Mitochondrion              1.7               0.25              2.9     0.16
   *Lipa*                        Lipolysis                           Lysosome                   3.7               \<0.05            6.1     \<0.05
   *Lpl*                         Lipolysis                           Plasma membrane            15.4              \<0.05            121.1   \<0.05
   *Lrp1*                        Fatty acid transport                Plasma membrane            2.1               0.10              8.3     \<0.05
   *Pdk4*                        Carbohydrate metabolism             Mitochondrion              17.4              \<0.05            5.1     \<0.05
   *Pparg*                       Nuclear receptor                    Nucleus                    8.7               0.06              64.6    \<0.05
   *Ppargc1a*                    Pparg cofactor                      Nucleus                    6.0               0.09              23.9    \<0.05
   *Ppargc1b*                    Pparg cofactor                      Nucleus                    1.5               0.30              2.2     0.19
   *Scd1*                        Fatty acid desaturase               Endoplasmic reticulum      −2.2              0.07              2.6     \<0.05
   *Txnip*                       Carbohydrate metabolism             Mitochondrion              1.1               0.64              7.9     0.08
                                                                                                                                             
  *II. Oxidative stress genes*                                                                                                              
   *Aldh1a1*                     Oxidative stress                    Cytoplasm                  1.3               0.28              9.2     0.06
   *Aldh1a7*                     Oxidative stress                    Cytoplasm                  2.0               0.12              8.7     \<0.05
   *Aldh3a1*                     Oxidative stress                    Cytoplasm                  4.8               0.19              11.8    \<0.05
   *Aldh3b1*                     Oxidative stress                    Cytoplasm                  3.7               0.16              9.7     \<0.05
   *Aldh7a1*                     Oxidative stress                    Cytoplasm                  4.9               \<0.05            2.9     0.12
   *Aox3*                        Oxidative stress                    Cytoplasm                  105.9             0.20              92.6    \<0.05
   *Casp4*                       Cell death                          Endoplasmic reticulum      5.0               \<0.05            21.6    \<0.05
   *Cat*                         Oxidative stress                    Mitochondrion              1.2               0.36              4.1     \<0.05
   *Cyp17a1*                     Oxidative stress                    Mitochondrion              3.5               \<0.05            4.5     0.09
   *Dhrs3*                       Oxidative stress                    Plasma membrane            13.8              0.23              31.9    \<0.05
   *Gsta2*                       Oxidative stress                    Cytoplasm                  3.9               0.07              18.7    0.24
   *Sirt5*                       Oxidative stress                    Mitochondrion              1.9               0.13              2.8     0.08
   *Sod3*                        Oxidative stress                    Extracellular              5.1               \<0.05            8.1     0.11
                                                                                                                                             
  *III. Differentiation genes*                                                                                                              
   *Ar*                          Steroid receptor                    Cytoplasm, nucleus         3.5               \<0.05            10.8    \<0.05
   *Krt14*                       Basal cell keratin                  Plasma membrane            −1.2              0.60              4.1     0.14
   *Pbsn*                        Prostate-specific differentiation   Extracellular              −1.7              0.41              2.7     0.19
   *Pten*                        Lipid and protein phosphatase       Plasma membrane            1.5               0.14              2.7     \<0.05
   *Trp63*                       Basal cell marker                   Nucleus                    3.3               \<0.05            8.0     0.17
   *Acta2*                       Smooth muscle marker                Structural                 1.5               0.28              1.9     \<0.05

###### Comparison of gene expression from harvested tissues of control, TZD- or HFD-treated mice by qRT-PCR

                                                                                                                         **Fold induction**                    
  ---------------------------------------------------- -------------------------------------- -------------------------- -------------------- ------- -------- --------
  *I. TZD-regulated genes in adipose*                                                                                                                          
   *Dgat2*                                             Triglyceride synthesis                 Endoplasmic reticulum      2459.2               4.4     53.1     8.3
   *Elovl4*                                            Fatty acid elongation                  Endoplasmic reticulum      16.5                 4.0     −1.3     −9.4
   *Fetub*                                             Insulin responsiveness                 Extracellular              223.3                5.7     −96.8    124.6
   *Gsta2*                                             Oxidative stress                       Cytoplasm                  21.5                 115.5   −1.5     −9.7
   *Ppargc1b*                                          Pparg cofactor                         Nucleus                    6.3                  1.9     −2.0     5.1
   *Sirt5*                                             Oxidative stress                       Cytoplasm                  1492.8               1.4     −1.9     −11.5
   *Trp63*                                             Prostate basal cell/adipocyte marker   Nucleus                    153.9                2.1     −36.3    6.2
   *Nox1*                                              Oxidative stress                       Cytoplasm                  508.9                2.7     −1.1     −1.3
   *Nfkb2*                                             Oxidative stress, inflammation         Cytoplasm, nucleus         63.8                 2.9     −3.2     −1.5
                                                                                                                                                                
  *II. TZD-regulated genes in prostate*                                                                                                                        
   *Acsf2*                                             Fatty acid oxidation                   Mitochondrion              5.7                  1.1     6.2      −5.4
   *Acta2*                                             Smooth muscle marker                   Structural                 −2.3                 2.7     9.5      −41.2
   *Adipor1*                                           Fatty acid oxidation                   Plasma membrane            2.0                  2.3     97.7     −171.4
   *Ar*                                                Steroid receptor                       Cytoplasm, nucleus         1.4                  2.1     33.8     −81.1
   *Cd36*                                              Long chain fatty acid metabolism       Cytoplasm, mitochondrion   −1.4                 4.7     48.3     3
   *Cd68*                                              Fatty acid transport                   Lysosome                   −3.7                 2.8     473.5    −31.3
   *Dagla*                                             Lipolysis                              Plasma membrane            −2.9                 −1.0    7.8      −77.4
   *Fabp4*                                             Fatty acid transport                   Cytoplasm, nucleus         −252.5               7.3     7669.7   −169.6
   *Fbp2*                                              Carbohydrate metabolism                Cytoplasm                  −1.8                 11.0    122.3    −13.6
   *Glul*                                              Glutamine catabolism                   Mitochondrion              −26.8                1.6     223.2    −57.8
   *Krt14*                                             Basal cell keratin                     Plasma membrane            1.8                  −2.5    5.2      −5.1
   *Lpl*                                               Lipolysis                              Plasma membrane            4.1                  7.8     1035.7   −4.7
   *Pbsn*                                              Prostate-specific differentiation      Extracellular              −135.3               −1.6    414.3    −249.9
   *Pdk4*                                              Carbohydrate metabolism                Mitochondrion              2.3                  14.7    7047.8   −57.3
   *Tgm2*                                              Wound healing                          Cytoplasm, nucleus         7.8                  11.6    9939.9   −123.4
                                                                                                                                                                
  *III. TZD-regulated genes in adipose and prostate*                                                                                                           
   *Acot1*                                             Long chain fatty acid metabolism       Cytoplasm                  3.0                  36.5    38.9     −254.1
   *Cat*                                               Oxidative stress                       Mitochondrion              250.3                5.4     68.0     −9.4
   *Lipa*                                              Lipolysis                              Lysosome                   9.8                  2.1     4.7      −1.5
   *Pparg*                                             Nuclear receptor                       Nucleus                    −11.3                9.7     76.1     −3.7
   *Ppargc1a*                                          Pparg cofactor                         Nucleus                    31.5                 5.8     5.1      −2.8
   *Pten*                                              Protein and lipid phosphatase          Cytoplasm, nucleus         36.2                 1.7     49.7     −97.9
   *Scd1*                                              Fatty acid desaturase                  Endoplasmic reticulum      21.9                 13.2    128.0    −4.3
   *Txnip*                                             Carbohydrate metabolism                Plasma membrane, nucleus   1.0                  14.7    60.0     −2.4
